Gynecological morcellation
Morcellation systems for hysterectomies and myomectomies
Hinzugefügt:
Statement on the dangers of electrical morcellation by the AGE
Based on the FDA’s communication of April 17, 2014, which warns against the use of electronic morcellation due to the possibility of spreading undetected cancer tissue, the AAGL and AGE have now issued statements that, on balance, continue to see electronic morcellation as a clinically useful application, even taking into account the known risks.
In response to the FDA warning, WISAP conducted a new clinical evaluation of the POWER DRIVE morcellation system and also concluded that the clinical benefits outweigh the risks. WISAP therefore agrees with AGE’s statement:
Hinzugefügt: AGE statement dated November 18, 2014
“From the AGE’s point of view, electrical morcellation is important for many patients with symptomatic fibroids. Instead of an abdominal hysterectomy, a minimally invasive laparoscopic hysterectomy or organ-preserving myomectomy can be performed for many women with the corresponding advantages. The ban on electrical morcellation would probably result in higher morbidity and mortality among patients. However, all patients must be informed about the low probability of malignant disease.